TransDigm Group Total Cost of Revenue increased by 10.7% to $1.03B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.9%, from $876.00M to $1.03B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 11.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $563.00M | $554.00M | $533.00M | $591.00M | $582.00M | $624.00M | $604.00M | $663.00M | $715.00M | $760.00M | $747.00M | $767.00M | $826.00M | $927.00M | $771.00M | $876.00M | $905.00M | $967.00M | $933.00M | $1.03B |
| QoQ Change | — | -1.6% | -3.8% | +10.9% | -1.5% | +7.2% | -3.2% | +9.8% | +7.8% | +6.3% | -1.7% | +2.7% | +7.7% | +12.2% | -16.8% | +13.6% | +3.3% | +6.9% | -3.5% | +10.7% |
| YoY Change | — | — | — | — | +3.4% | +12.6% | +13.3% | +12.2% | +22.9% | +21.8% | +23.7% | +15.7% | +15.5% | +22.0% | +3.2% | +14.2% | +9.6% | +4.3% | +21.0% | +17.9% |